Business
Pfizer to develop mRNA vaccines without BioNTech
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
Pfizer Inc (NYSE: PFE)‘s success in developing an effective COVID-19 vaccine in record time has given the pharmaceutical giant the confidence to invest heavily in the technology that underpins that vaccine. In an interview with The Wall Street Journal on Tuesday, CEO Albert Bourla revealed that Pfizer plans to become a leader in the development of new vaccines that rely on messenger RNA (mRNA).
Unfortunately for BioNTech (NASDAQ: BNTX), those plans don’t rely on a continuation of the collaboration agreement that brought the world its first authorized mRNA-based vaccine. According to Bourla, Pfizer doesn’t need to work with…
-
General20 hours agoAs Iran-Australia relations plunge to a new low, Tehran faces another diplomatic setback
-
Noosa News16 hours agoBrisbane nation’s third-youngest capital; Leaders condemn anti-immigration rally
-
Noosa News20 hours agoPSPA declaration, Glenorchy (Fraser Coast)
-
Noosa News6 hours agoPill checking to resume in Queensland months after government axed funding